Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Cristina Díaz-Tejeiro"'
Autor:
Lucía Paniagua-Herranz, Cristina Díaz-Tejeiro, Adrián Sanvicente, Jorge Bartolomé, Cristina Nieto-Jiménez, Alberto Ocana
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Therapeutic strategies targeting non-adaptive immune cells are currently in clinical development. γδT cells are a small subtype of T cells (1-10% of total T cells) that mediate their effector function without the necessity of the antigen presenting
Externí odkaz:
https://doaj.org/article/7d774cf911074c7781f4b84be65f5c1a
Autor:
Alfonso López de Sá, Cristina Díaz-Tejeiro, Elisa Poyatos-Racionero, Cristina Nieto-Jiménez, Lucía Paniagua-Herranz, Adrián Sanvicente, Emiliano Calvo, Pedro Pérez-Segura, Víctor Moreno, Francisco Moris, Alberto Ocana
Publikováno v:
Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-13 (2023)
Abstract Antibody–drug conjugates (ADCs) have emerged as a novel therapeutic strategy that has successfully reached patient treatment in different clinical scenarios. ADCs are formed by an antibody against a specific tumor-associated antigen (TAA),
Externí odkaz:
https://doaj.org/article/c72087b5dfa54ed0aa029fccbd8b25e2
Autor:
Adrián Sanvicente García, Manuel Pedregal, Lucía Paniagua-Herranz, Cristina Díaz-Tejeiro, Cristina Nieto-Jiménez, Pedro Pérez Segura, Gyöngyi Munkácsy, Balázs Győrffy, Emiliano Calvo, Víctor Moreno, Alberto Ocaña
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 10, p 5345 (2024)
The identification of targets that are expressed on the cell membrane is a main goal in cancer research. The Lymphocyte Antigen 6 Family Member G6D (LY6G6D) gene codes for a protein that is mainly present on the surface of colorectal cancer (CRC) cel
Externí odkaz:
https://doaj.org/article/12a3623042cd4919b4effc47d41c292d
Autor:
Adrián Sanvicente, Cristina Díaz-Tejeiro, Cristina Nieto-Jiménez, Lucia Paniagua-Herranz, Igor López Cade, Győrffy Balázs, Víctor Moreno, Pedro Pérez-Segura, Emiliano Calvo, Alberto Ocaña
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 7, p 3987 (2024)
Immuno-oncology has gained momentum with the approval of antibodies with clinical activities in different indications. Unfortunately, for anti-PD (L)1 agents in monotherapy, only half of the treated population achieves a clinical response. For other
Externí odkaz:
https://doaj.org/article/6cdddf10de4345e7aa95611bb8650b3a
Autor:
Cristina Nieto‐Jiménez, Adrián Sanvicente, Cristina Díaz‐Tejeiro, Víctor Moreno, Alfonso lopez deSá, Emiliano Calvo, Joaquín Martínez‐López, Pedro Pérez‐Segura, Alberto Ocaña
Publikováno v:
Clinical and Translational Medicine, Vol 13, Iss 9, Pp n/a-n/a (2023)
Abstract Introduction Antibody‐drug conjugates (ADCs) are a family of therapeutic agents that have demonstrated clinical activity in several indications. Material and methods In this article, we performed a deep analysis of their clinical landscape
Externí odkaz:
https://doaj.org/article/445511a833964204a594eaf0a23f9c5e
Autor:
Lucía Paniagua-Herranz, Irene Moreno, Cristina Nieto-Jiménez, Esther Garcia-Lorenzo, Cristina Díaz-Tejeiro, Adrián Sanvicente, Bernard Doger, Manuel Pedregal, Jorge Ramón, Jorge Bartolomé, Arancha Manzano, Balázs Gyorffy, Álvaro Gutierrez-Uzquiza, Pedro Pérez Segura, Emiliano Calvo, Víctor Moreno, Alberto Ocana
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 4, p 2222 (2024)
The identification of surfaceome proteins is a main goal in cancer research to design antibody-based therapeutic strategies. T cell engagers based on KLK2, a kallikrein specifically expressed in prostate cancer (PRAD), are currently in early clinical
Externí odkaz:
https://doaj.org/article/c3b8403f9c0744b0baf28b3578bf3380
Autor:
Lucía Paniagua-Herranz, Bernard Doger, Cristina Díaz-Tejeiro, Adrián Sanvicente, Cristina Nieto-Jiménez, Víctor Moreno, Pedro Pérez Segura, Balazs Gyorffy, Emiliano Calvo, Alberto Ocana
Publikováno v:
Cancers, Vol 15, Iss 12, p 3250 (2023)
Background: The identification of proteins in the cellular membrane of the tumoral cell is a key to the design of therapeutic agents. Recently, the bi-specific antibody amivantamab, targeting the oncogenic membrane proteins EGFR and MET, received reg
Externí odkaz:
https://doaj.org/article/1900dd6469094e079bc45ccf5b2f26bf
Autor:
Igor López-Cade, Vanesa García-Barberán, Esther Cabañas Morafraile, Cristina Díaz-Tejeiro, Cristina Saiz-Ladera, Adrián Sanvicente, Pedro Pérez Segura, Atanasio Pandiella, Balázs Győrffy, Alberto Ocaña
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Identification of genomic alterations that influence the immune response within the tumor microenvironment is mandatory in order to identify druggable vulnerabilities. In this article, by interrogating public genomic datasets we describe copy number
Externí odkaz:
https://doaj.org/article/1300f7e3084a44b790a2bfcef5cea1aa
Autor:
Ocana, Lucía Paniagua-Herranz, Bernard Doger, Cristina Díaz-Tejeiro, Adrián Sanvicente, Cristina Nieto-Jiménez, Víctor Moreno, Pedro Pérez Segura, Balazs Gyorffy, Emiliano Calvo, Alberto
Publikováno v:
Cancers; Volume 15; Issue 12; Pages: 3250
Background: The identification of proteins in the cellular membrane of the tumoral cell is a key to the design of therapeutic agents. Recently, the bi-specific antibody amivantamab, targeting the oncogenic membrane proteins EGFR and MET, received reg